Company / Depreciation & Amortization
Rein Therapeutics, Inc. Depreciation & Amortization History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$63.0K
FY2025
5-year range
$63.0K / $169.0K
FY2021-FY2025
Trend
-47.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has fluctuated over the past 9 years, ranging from $63,000 in FY2025 to $325,000 in FY2017.
Based on SEC 10-K filings.
$63,000 in FY2025 with a 5-year CAGR of -16.5%.
Improved from $169,000 to $63,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -19.6%
- 5-Year CAGR
- -16.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -16.5%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 47.1% year-over-year.
- Peak depreciation & amortization was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $63.0K | -47.1% |
| FY2024 | $119.0K | -29.6% |
| FY2023 | $169.0K | +39.7% |
| FY2022 | $121.0K | -25.8% |
| FY2021 | $163.0K | +5.2% |
| FY2020 | $155.0K | -28.9% |
| FY2019 | $218.0K | +69.0% |
| FY2018 | $129.0K | -60.3% |
| FY2017 | $325.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026